NCT03194685View on ClinicalTrials.gov

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

May 5, 2017

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
AML, Adult
Interventions
DRUG

FF-10101-01

FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.

Trial Locations (7)

14263

Roswell Park Comprehensive Cancer Center, Buffalo

19104

University of Pennsylvania, Philadelphia

21287

Johns Hopkins Hospital - Sidney Kimmel Cancer Center, Baltimore

60611

Northwestern University, Chicago

90095

University of California Los Angeles, David Geffen School of Medicine, Los Angeles

94143

University Of California, San Francisco School of Medicine, San Francisco

02114

Massachusetts General Hospital Cancer Center, Boston

Sponsors
All Listed Sponsors
lead

Fujifilm Pharmaceuticals U.S.A., Inc.

INDUSTRY